Prophylactic oophorectomy: Clinical considerations

Seminars in Surgical Oncology

Volumn 19, Issue 1, 2000, Pages 20-27

  Gotlieb, Walter H ^a,b   Baruch, Gilad Ben ^a   Friedman, Eitan ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

BRCA1 genes; Breast neoplasms epidemiology genetics; Genetic markers; Genetic predisposition to disease; Genetic screening; Hereditary nonpolyposis colorectal neoplasms; Hysterectomy; Non steroidal estrogens; Ovarian neoplasms epidemiology genetics prevention and control surgery; Ovariectomy; Prophylactic surgery

Indexed keywords

ESTROGEN;

ADULT; AGED; BREAST CANCER; CANCER CONTROL; CANCER SURGERY; FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS;

AGE FACTORS; CONTRACEPTIVES, ORAL; FEMALE; GENES, BRCA1; GENETIC SCREENING; HORMONE REPLACEMENT THERAPY; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PRIMARY PREVENTION;

EID: 0033944968     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2388(200007/08)19:1<20::AID-SSU4>3.0.CO;2-2     Document Type: Review

References (71)

1. Devesa SS, Blot WJ, Stone BJ, et al: Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175-182.
2. Gotlieb WH, Berek JS: Advances in the biology of gynecologic cancer [Review]. Curr Opin Oncol 1994;6:513-518.
3. New directions in ovarian cancer research: report of the Strategic Planning Conference, December 8-9, 1997. Bethesda: National Cancer Institute; 1998.
4. Dauplat J, Lefranc JP, Bremond A: [Prevention of ovarian cancer by prophylactic ovariectomy] [Review]. Chirurgie 1998;123:405-408. (Fre)
5. Li FP: Cancer control in susceptible groups: opportunities and challenges [Review]. J Clin Oncol 1999;17:719-725.
6. Miller SM, Fang CY, Manne SL, et al: Decision making about prophylactic oophorectomy among at-risk women: psychological influences and implications. Gynecol Oncol 1999;75:406-412.
7. Averette HE, Nguyen HN: The role of prophylactic oophorectomy in cancer prevention [Review]. Gynecol Oncol 1994;55(3 Pt 2):S38-41.
8. Olsen JH, Seersholm N, Boice JD Jr, et al: Cancer risk in close relatives of women with early-onset breast cancer - a population-based incidence study. Br J Cancer 1999;79:673-679.
9. Fishel R, Lescoe MK, Rao MR, et al: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer [published erratum appears in Cell 1994;77:167]. Cell 1993;75:1027-1038.
10. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA 1. Science 1994;266(5182):66-70.
11. Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265(5181):2088-2090.
12. Ford D, Easton DF: The genetics of breast and ovarian cancer [Review]. Br J Cancer 1995;72:805-812.
13. King MC, Rowell S, Love SM: Inherited breast and ovarian cancer. What are the risks? What are the choices. JAMA 1993;269:1975-1980.
14. Gotlieb WH, Friedman E, Bar-Sade RB, et al: Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998;90:995-1000.
15. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
16. Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-1250.
17. Gayther SA, Mangion J, Russell P, et al: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-105.
18. Phelan CM, Rebbeck TR, Weber BL, et al: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996;12:309-311.
19. Richards CS, Ward PA, Roa BB, et al: Screening for 185delAG in the Ashkenazim. Am J Hum Genet 1997;60:1085-1098.
20. Gotlieb WH, Berek JS: Le bon usage des marqueurs biologiques [The proper application of biological markers]. In Dauplat J, Guastala JP (eds): "Cancer de l'ovaire." Paris: Arnette Blackwell; 1996. p. 121-133. (Fre)
21. Bell R, Petticrew M, Sheldon T: The performance of screening tests for ovarian cancer: results of a systematic review [Review]. Br J Obstet Gynaecol 1998;105:1136-1147.
22. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353(9160):1207-1210.
23. Harris R, Whittemore AS, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992;136:1204-1211.
24. Gotlieb WH, Flikker S, Davidson B, et al: Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998;82:141-146.
25. Venn A, Watson L, Bruinsma F, et al: Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354(9190):1586-1590.
26. Potashnik G, Lerner-Geva L, Genkin L, et al: Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999;71:853-859.
27. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-655.
28. Beral V, Hermon C, Kay C, et al: Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999;318(7176):96-100.
29. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
30. Ursin G, Henderson BE, Haile RW, et al: Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997;57:3678-3681.
31. Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995;(17):33-35.
32. Meltomaa SS, Taalikka MO, Helenius HY, Makinen JI: Complications and long-term outcomes after adnexal surgery by laparotomy and laparoscopy. J Am Assoc Gynecol Laparosc 1999;6: 463-469.
33. Tamussino KF, Lang PF, Breinl E: Ureteral complications with operative gynecologic laparoscopy. Am J Obstet Gynecol 1998; 178:967-970.
34. Leminen A, Lehtovirta P: Spread of ovarian cancer after laparoscopic surgery: report of eight cases. Gynecol Oncol 1999;75:387-390.
35. Karakoc B, Erenus M: Compliance considerations with hormone replacement therapy. Menopause 1998;5:102-106.
36. Hammond CB: Women's concerns with hormone replacement therapy - compliance issues [Review]. Fertil Steril 1994;62(6 Suppl 2):157S-160S.
37. Siddle N, Sarrel P, Whitehead M: The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review [Review]. Fertil Steril 1987;47:94-100.
38. Watson NR, Studd JW, Garnett T, et al: Bone loss after hysterectomy with ovarian conservation. Obstet Gynecol 1995;86:72-77.
39. Shoham Z: Should prophylactic oophorectomy be performed on post-menopausal women undergoing laparotomy or laparoscopy for non-gynaecological indications? Hum Reprod 1997;12:201-202.
40. Sightler SE, Boike GM, Estape RE, Averette HE: Ovarian cancer in women with prior hysterectomy: a 14-year experience at the University of Miami [Review]. Obstet Gynecol 1991;78:681-684.
41. Averette HE, Hoskins W, Nguyen HN, et al: National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer 1993;71(4 Suppl): 1629-1638.
42. Loft A, Lidegaard O, Tabor A: Incidence of ovarian cancer after hysterectomy: a nationwide controlled follow up. Br J Obstet Gynaecol 1997;104:1296-1301.
43. Fine BA, Yazigi R, Risser R: Prognosis of ovarian cancer developing in the residual ovary. Gynecol Oncol 1991;43:164-166.
44. Yaegashi N, Sato S, Yajima A: Incidence of ovarian cancer in women with prior hysterectomy in Japan. Gynecol Oncol 1998;68:244-246.
45. Koves I, Vamosi-Nagy I, Besznyak I: Ovarian metastases of colorectal tumours. Eur J Surg Oncol 1993;19:633-635.
46. Schutt U, Wedell J, Koppen P, Reichmann J: [Preventive ovariectomy in colorectal cancer] [Review]. Chirurg 1993;64:1040-1043. (Ger)
47. Gemos K, Rizzotti L, Tsardis P, et al: [Indications for prophylactic ovariectomy in patients with colorectal carcinoma]. Minerva Chir 1995;50:89-92. (Ita)
48. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-1479.
49. Meijer WJ, van Lindert AC: Prophylactic oophorectomy [Review]. Eur J Obstet Gynecol Reprod Biol 1992;47:59-65.
50. Houlston RS, Hampson J, Collins WP, et al: Correlation in ages at death from familial ovarian cancer among sisters. Gynecol Oncol 1992;47:253-254.
51. Grann VR, Whang W, Jacobson JS, et al: Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 1999;17:494-500.
52. Genazzani AR, Gambacciani M: Hormone replacement therapy: the perspectives for the 21st century [Review]. Maturitas 1999;32:11-17.
53. Bachmann GA: Androgen cotherapy in menopause: evolving benefits and challenges [Review]. Am J Obstet Gynecol 1999;180(3Pt 2):308-311.
54. Davis SR: The therapeutic use of androgens in women [Review]. J Steroid Biochem Mol Biol 1999;69:177-184.
55. Colditz GA, Willett WC, Stampfer MJ, et al: Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
56. Ross RK, Paganini-Hill A, Mack TM, Henderson BE: Cardiovascular benefits of estrogen replacement therapy [Review]. Am J Obstet Gynecol 1989:160(5 Pt 2):1301-1306.
57. Speroff T, Dawson NV, Speroff L, Haber RJ: A risk-benefit analysis of elective bilateral oophorectomy: effect of changes in compliance with estrogen therapy on outcome. Am J Obstet Gynecol 1991;164(1 Pt 1):165-174.
58. Kuiper GG, van den Bemd GJ, van Leeuwen JP: Estrogen receptor and the SERM concept [Review]. J Endocrinol Invest 1999;22:594-603.
59. Murkies AL, Wilcox G, Davis SR: Clinical review 92: Phytoestrogens [Review]. J Clin Endocrinol Metab 1998;83:297-303.
60. Davis SR, Dalais FS, Simpson ER, Murkies AL: Phytoestrogens in health and disease [Review]. Recent Prog Horm Res 1999;54: 185-211.
61. Piver MS, Wong C: Prophylactic oophorectomy: a century-long dilemma [Review]. Hum Reprod 1997:12:205-206.
62. Grann VR, Panageas KS, Whang W, et al: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979-985.
63. Schrag D, Kuntz KM, Garber JE, Weeks JC: Decision analysis -effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations [published erratum appears in N Engl J Med 1997;337:434]. N Engl J Med 1997;336:1465-1471.
64. Salazar H, Godwin AK, Daly MB, et al: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-1820.
65. Stratton JF, Buckley CH, Lowe D, Ponder BA: Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 1999;91:626-628.
66. Tonin P, Weber B, Offit K, et al: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families [Review]. Nat Med 1996;2:1179-1183.
67. Muto MG, Welch WR, Mok SC, et al: Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995;55:490-492.
68. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180:917-928.
69. Bandera CA, Muto MG, Schorge JO, et al: BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998;92(4 Pt 1):596-600.
70. Schorge JO, Muto MG, Welch WR, et al: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998;90:841-845.
71. Piver MS, Jishi MF, Tsukada Y, Nava G: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751-2755.